ArticleJournal of managed care & specialty pharmacy2025
Brand-to-brand nonmedical switching among interleukin-17 inhibitors or other biologics: Implications of a formulary change.
A Mark Fendrick et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.